USP Helps Expand Worldwide Access to Tuberculosis Drugs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

USP Helps Expand Worldwide Access to Tuberculosis Drugs



The US Pharmacopeial Convention (USP) and the US Agency for International Development (USAID) through the Promoting the Quality of Medicines (PQM) program has funded Capreomycin, the first “second line” anti-tuberculosis API for injectables. Capreomycin has been assessed by the World Health Organization (WHO) and given prequalification status.

Since 2009, USAID and USP, through the PQM program, have been providing technical and professional assistance to manufacturers and regulatory agencies in countries around the world to strengthen quality assurance systems for medicines, guide manufacturers toward compliance with WHO good manufacturing practices, and help manufacturers prepare product dossiers for submission to the WHO prequalification program.

As a result, the PQM program has helped three drugs achieve prequalification status including: Cycloserine, an anti-tuberculosis medicine; ZinCfant, a zinc product for managing diarrhea in children; and Capreomycin.

Source: USP

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here